middle.news
How Is Anteris Using $80M IPO Proceeds to Advance DurAVR Heart Valve?
2:36am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How Is Anteris Using $80M IPO Proceeds to Advance DurAVR Heart Valve?
2:36am on Monday 2nd of June, 2025 AEST
Key Points
Q1 2025 net loss of $21.9 million, up 36% year-over-year
R&D expenses rose 42% to $16.5 million, focusing on manufacturing scale-up and clinical trial prep
Net sales declined 27% to $0.6 million due to reduced tissue product demand
Raised $80 million net from December 2024 IPO, funding DurAVR development and debt repayment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE